Anavex Announces Positive Phase 1 Data for ANAVEX 2-73, Lead Candidate for the Treatment of Alzheimer’s

Data Presented at CNS Summit 2014 Supports Commencement of Phase 2 Clinical Trial in Alzheimer’s Patients NEW YORK, NY, November 17, 2014 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) announced full data results from the Phase 1 clinical trial of ANAVEX 2-73, the Company’s lead investigational oral treatment for Alzheimer’s, which…